特应性皮炎的新疗法:其他治疗类别
本文为非系统性文献综述,检索PubMed和ClinicalTrials.gov,评估用于特应性皮炎(AD)的多种新机制药物,包括omiganan、tapinarof、PR022、asimadoline、DS107、ZPL-389、secukinumab和fezakinumab,分析其作用机制、疗效与安全性数据。许多药物临床数据有限,但具有治疗潜力,需继续研究。
要点
- 综述汇总了8种不同机制的新型AD治疗药物。
- 多数药物临床数据有限,需进一步研究验证。
- 多种药物显示出治疗潜力,值得继续研发。
核心结论
- 随着对AD发病机制的理解深入,多种独特机制药物被研究用于AD治疗,许多具有治疗前景,需继续研发。
研究设计与样本
- 非系统性文献综述,检索PubMed和ClinicalTrials.gov,主要寻找随机对照试验,也包括其他类型研究。
主要发现
- 综述呈现了omiganan(抗菌肽)、tapinarof(非甾体抗炎药)、PR022(次氯酸)、asimadoline(κ阿片受体激动剂)、DS107(二高-γ-亚麻酸)、ZPL-389(组胺H4受体拮抗剂)、secukinumab(IL-17A抑制剂)和fezakinumab(IL-22抑制剂)的数据。
临床怎么用
- 临床可关注这些新机制药物的研究进展,但目前多数药物证据有限,尚不能常规推荐。
局限性
- 许多所述药物的临床数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A wide array of miscellaneous agents is being studied for the treatment of atopic dermatitis (AD), including targeted topical, oral systemic, and biologic agents. OBJECTIVE: To review the known efficacy and safety to date for such agents being studied for the treatment of AD. METHODS: A nonsystematic review of the literature was performed. PubMed and ClinicalTrials.gov were searched for studies assessing agents not described previously for the treatment of AD. Randomized controlled trials were primarily sought, but other study types were also included if they contained pertinent data. Agents are presented by mechanism of action, with analysis of mechanism of action and data regarding efficacy and safety in patients with AD. RESULTS: Data regarding the following agents are presented: omiganan (an antimicrobial peptide), tapinarof (a nonsteroidal anti-inflammatory agent), PR022 (hypochlorous acid), asimadoline (a κ-opioid agonist), DS107 (dihomo-γ-linolenic acid), ZPL-389 (a histamine H4 receptor antagonist), secukinumab (an interleukin 17A inhibitor), and fezakinumab (interleukin 22 inhibitor). LIMITATIONS: Limited clinical data exist for many of the described agents. CONCLUSIONS: As recent research has improved our understanding of AD pathogenesis, various agents with unique mechanisms of action have been studied for the treatment of AD. Many of these hold great therapeutic promise for AD, and continued research and development is warranted.
引用
- Vakharia PP, Silverberg JI. New therapies for atopic dermatitis: Additional treatment classes. J Am Acad Dermatol. 2017. PMID: 29248520. doi:10.1016/j.jaad.2017.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。